Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 9/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 11/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 11/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 11/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 11/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 11/20 | 0.54 |
| ▸ | HDAC10 | Q969S8 | 11/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 11/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 11/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 0.54 |
| ▸ | HDAC9 | Q9UKV0 | 11/20 | 0.54 |
| ▸ | HDAC5 | Q9UQL6 | 11/20 | 0.54 |
| ▸ | MTOR | P42345 | 1/20 | 0.54 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12910283 | 0.91 | HDAC3 (0.57) | PIK3CAHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL12910286 | 0.89 | PIK3CA (0.52) | PIK3CAHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL12910292 | 0.89 | PIK3CA (0.53) | PIK3CAHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL12910282 | 0.87 | PIK3CA (0.56) | PIK3CAHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL12537228 | 0.87 | HDAC3 (0.58) | PIK3CAHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL944931 | 0.86 | PIK3CA (0.54) | PIK3CAHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL945723 | 0.86 | PIK3CA (0.54) | PIK3CAHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL12910276 | 0.85 | PIK3CA (0.52) | PIK3CAHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL1114143 | 0.84 | PIK3CA (0.59) | PIK3CAHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL12910255 | 0.83 | PIK3CA (0.57) | PIK3CAHDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513221-B2 | PI3K isoform selective inhibitors | Xcovery Holding, LLC (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513221-B2 | PI3K isoform selective inhibitors | Xcovery Holding, LLC (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513221-B2 | PI3K isoform selective inhibitors | Xcovery Holding, LLC (US) | 2013-08-20 | — | — | US | disclosed |
| US-20110130395-A1 | P13K ISOFORM SELECTIVE INHIBITORS | XCOVERY HOLDING COMPANY LLC | 2011-06-02 | — | — | US | disclosed |
| US-20110130395-A1 | P13K ISOFORM SELECTIVE INHIBITORS | XCOVERY HOLDING COMPANY LLC | 2011-06-02 | — | — | US | disclosed |
| US-20110130395-A1 | P13K ISOFORM SELECTIVE INHIBITORS | XCOVERY HOLDING COMPANY LLC | 2011-06-02 | — | — | US | disclosed |
| EP-2307414-A2 | PI3K ISOFORM SELECTIVE INHIBITORS | Xcovery Holding Company LLC (US) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010005558-A2 | PI3K ISOFORM SELECTIVE INHIBITORS | XCOVERY, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130395-A1 | P13K ISOFORM SELECTIVE INHIBITORS | PI4KA, PIK3CA, PIKFYVE | PIK3CA 2/4885HDAC3 1801/4885HDAC4 2883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.